These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26022230)

  • 21. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.
    Goldhar HA; Yan AT; Ko DT; Earle CC; Tomlinson GA; Trudeau ME; Krahn MD; Krzyzanowska MK; Pal RS; Brezden-Masley C; Gavura S; Lien K; Chan KK
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26476433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
    Bowles EJ; Wellman R; Feigelson HS; Onitilo AA; Freedman AN; Delate T; Allen LA; Nekhlyudov L; Goddard KA; Davis RL; Habel LA; Yood MU; McCarty C; Magid DJ; Wagner EH;
    J Natl Cancer Inst; 2012 Sep; 104(17):1293-305. PubMed ID: 22949432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of Early Radiation-Induced Changes in Left Ventricular Function by Myocardial Strain Imaging After Breast Radiation Therapy.
    Yu AF; Ho AY; Braunstein LZ; Thor ME; Lee Chuy K; Eaton A; Mara E; Cahlon O; Dang CT; Oeffinger KC; Steingart RM; Liu JE
    J Am Soc Echocardiogr; 2019 Apr; 32(4):521-528. PubMed ID: 30826225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.
    Gripp EA; Oliveira GE; Feijó LA; Garcia MI; Xavier SS; Sousa AS
    Arq Bras Cardiol; 2018 Feb; 110(2):140-150. PubMed ID: 29561992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiac Function After Multimodal Breast Cancer Therapy Assessed With Functional Magnetic Resonance Imaging and Echocardiography Imaging.
    Heggemann F; Grotz H; Welzel G; Dösch C; Hansmann J; Kraus-Tiefenbacher U; Attenberger U; Schönberg SO; Borggrefe M; Wenz F; Papavassiliu T; Lohr F
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):836-44. PubMed ID: 26530752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
    Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
    J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC).
    Zito C; Manganaro R; Cusmà Piccione M; Madonna R; Monte I; Novo G; Mercurio V; Longobardo L; Cadeddu Dessalvi C; Deidda M; Pagliaro P; Spallarossa P; Costantino R; Santarpia M; Altavilla G; Carerj S; Tocchetti CG
    Eur Heart J Cardiovasc Imaging; 2021 Mar; 22(4):406-415. PubMed ID: 33432333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy.
    Thavendiranathan P; Grant AD; Negishi T; Plana JC; Popović ZB; Marwick TH
    J Am Coll Cardiol; 2013 Jan; 61(1):77-84. PubMed ID: 23199515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines.
    Mousavi N; Tan TC; Ali M; Halpern EF; Wang L; Scherrer-Crosbie M
    Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):977-84. PubMed ID: 25925220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).
    de Azambuja E; Procter MJ; van Veldhuisen DJ; Agbor-Tarh D; Metzger-Filho O; Steinseifer J; Untch M; Smith IE; Gianni L; Baselga J; Jackisch C; Cameron DA; Bell R; Leyland-Jones B; Dowsett M; Gelber RD; Piccart-Gebhart MJ; Suter TM
    J Clin Oncol; 2014 Jul; 32(20):2159-65. PubMed ID: 24912899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
    Fallah-Rad N; Walker JR; Wassef A; Lytwyn M; Bohonis S; Fang T; Tian G; Kirkpatrick ID; Singal PK; Krahn M; Grenier D; Jassal DS
    J Am Coll Cardiol; 2011 May; 57(22):2263-70. PubMed ID: 21616287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodelling.
    Mizia-Stec K; Gościńska A; Mizia M; Haberka M; Chmiel A; Poborski W; Gąsior Z
    Kardiol Pol; 2013; 71(7):681-90. PubMed ID: 23907900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Left ventricular longitudinal systolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a long-term follow-up study focused on speckle tracking echocardiography.
    Sommer A; Poulsen SH; Mogensen J; Thuesen L; Egeblad H
    Eur J Echocardiogr; 2010 Dec; 11(10):883-8. PubMed ID: 20667848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Global and regional patterns of longitudinal strain in screening for chemotherapy-induced cardiotoxicity.
    Portugal G; Moura Branco L; Galrinho A; Mota Carmo M; Timóteo AT; Feliciano J; Abreu J; Duarte Oliveira S; Batarda L; Cruz Ferreira R
    Rev Port Cardiol; 2017 Jan; 36(1):9-15. PubMed ID: 27955938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trastuzumab-related cardiac events in the treatment of early breast cancer.
    Fried G; Regev T; Moskovitz M
    Breast Cancer Res Treat; 2013 Nov; 142(1):1-7. PubMed ID: 24154507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Trastuzumab-induced early cardiac dysfunction using two-dimensional Strain Echocardiography.
    Emren SV; Tuluce SY; Levent F; Tuluce K; Kalkan T; Yildiz Y; Alacacioğlu A; Kucukzeybek Y; Akyol M; Salman T
    Med Ultrason; 2015 Dec; 17(4):496-502. PubMed ID: 26649345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Left ventricular strain and strain rates are decreased in children with normal fractional shortening after exposure to anthracycline chemotherapy.
    Moon TJ; Miyamoto SD; Younoszai AK; Landeck BF
    Cardiol Young; 2014 Oct; 24(5):854-65. PubMed ID: 24044518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab.
    Hare JL; Brown JK; Leano R; Jenkins C; Woodward N; Marwick TH
    Am Heart J; 2009 Aug; 158(2):294-301. PubMed ID: 19619708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?
    Morris PG; Hudis CA
    J Clin Oncol; 2010 Jul; 28(21):3407-10. PubMed ID: 20530269
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.